Exploring the common mechanism of Yindan Xinnaotong soft capsule in the treatment of stroke and coronary heart disease through HIF1α-MMP9-mediated HIF1α signaling pathway
10.16438/j.0513-4870.2023-0073
- VernacularTitle:基于“异病同治”理论探讨银丹心脑通软胶囊通过HIF1α-MMP9介导的HIF1α信号通路治疗脑卒中和冠心病的共同机制
- Author:
Jie GAO
1
,
2
;
Yi-feng DONG
3
;
Si-meng WANG
3
;
Ru-shang HE
3
;
Ting-can JIANG
3
;
Ming-jiang WU
4
;
Hong-hua WU
3
;
Xing LI
5
;
Guan-wei FAN
6
;
Yan ZHU
3
;
Ming LV
3
Author Information
1. College of Traditional Chinese Medicine, Hebei University, Baoding 071002, China
2. State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
3. State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
4. Zunyi Medical and Pharmaceutical College, Zunyi 563000, China
5. Guizhou Bailing Group Pharmaceutical Co. Ltd., Guiyang 550000, China
6. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
- Publication Type:Research Article
- Keywords:
Yindan Xinnaotong soft capsule;
coronary heart disease;
stroke;
HIF1α signaling pathway;
same treatment to different diseases
- From:
Acta Pharmaceutica Sinica
2023;57(6):1401-1411
- CountryChina
- Language:Chinese
-
Abstract:
Coronary heart disease (CHD) and stroke are the most well-known cardiovascular diseases, which share many common pathological basis. Yindan Xinnaotong soft capsule (YDXNT) is a commonly used Chinese patent medicine in the treatment of stroke and CHD. However, its action of mechanism of co-treatment for stroke and CHD is still unclear. The aim of this study was to explore the common mechanism of YDXNT in co-treatment of CHD and stroke using network pharmacology, experimental verification and molecular docking. An integrated literature mining and databases of IPA, ETCM, HERB, Swiss Target Prediction, OMIM and GeneCards were used to screen and predict active ingredients and potential targets of YDXNT in co-treatment of CHD and stroke. The protein-protein interaction network, GO analysis and pathway analysis were analyzed by IPA software. The effect of YDXNT on core targets was verified by immunofluorescence. UPLC-QTOF/MS and molecular docking were used to screen and predict the main active constituents of YDXNT and their interactions with core targets. A total of 151 potential targets are predicted for YDXNT in co-treatment of CHD and stroke. Hypoxia-inducible factor-1α (HIF1α)-matrix metalloproteinase-9 (MMP9)-mediated HIF1α signaling pathway serves as one of the common mechanisms. YDXNT could reduce the increase of mitochondrial fluorescence intensity and the protein expression of HIF1α and MMP9 in HL-1 and HA induced by oxygen and glucose deprivation/reperfusion (OGD/R) in a dose-dependent manner. Baicalin may be the material basis for treating stroke and CHD with YDXNT. In conclusion, the HIF1α signaling pathway is one of the common key mechanisms of YDXNT in the co-treatment of stroke and CHD. The study provides support and basis for the in-depth scientific connotation of the traditional Chinese medicine theory of "same treatment to different diseases".
